Hatano K, Nonomura N (2023) Systemic therapies for metastatic castration-resistant prostate cancer: an updated review. World J Mens Health 41:769–784. https://doi.org/10.5534/wjmh.220200

Article  PubMed  PubMed Central  Google Scholar 

Hatano K, Nonomura N (2022) Genomic profiling of prostate cancer: an updated review. World J Mens Health 40:368–379. https://doi.org/10.5534/wjmh.210072

Article  PubMed  Google Scholar 

Marcus L, Lemery SJ, Keegan P, Pazdur R (2019) FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors. Clin Cancer Res 25:3753–3758. https://doi.org/10.1158/1078-0432.CCR-18-4070

Article  CAS  PubMed  Google Scholar 

Marcus L, Fashoyin-Aje LA, Donoghue M et al (2021) FDA approval summary: pembrolizumab for the treatment of tumor mutational burden-high solid tumors. Clin Cancer Res 27:4685–4689. https://doi.org/10.1158/1078-0432.CCR-21-0327

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vaishnavi A, Le AT, Doebele RC (2015) TRKing down an old oncogene in a new era of targeted therapy. Cancer Discov 5:25–34. https://doi.org/10.1158/2159-8290.CD-14-0765

Article  CAS  PubMed  Google Scholar 

Drilon A, Laetsch TW, Kummar S et al (2018) Efficacy of larotrectinib in TRK fusion–positive cancers in adults and children. N Engl J Med 378:731–739. https://doi.org/10.1056/NEJMoa1714448

Article  CAS  PubMed  PubMed Central  Google Scholar 

Doebele RC, Drilon A, Paz-Ares L et al (2020) Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials. Lancet Oncol 21:271–282. https://doi.org/10.1016/S1470-2045(19)30691-6

Article  CAS  PubMed  Google Scholar 

Westphalen CB, Krebs MG, Le Tourneau CL et al (2021) Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population. NPJ Precis Oncol 5:69. https://doi.org/10.1038/s41698-021-00206-y

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jiang T, Wang G, Liu Y et al (2021) Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers. Acta Pharm Sin B 11:355–372. https://doi.org/10.1016/j.apsb.2020.05.004

Article  CAS  PubMed  Google Scholar 

Hong DS, DuBois SG, Kummar S et al (2020) Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol 21:531–540. https://doi.org/10.1016/S1470-2045(19)30856-3

Article  CAS  PubMed  PubMed Central  Google Scholar 

Whaley RD, Tekin B, McCarthy MR et al (2024) NTRK3-rearranged prostatic acinar adenocarcinoma: report of a patient and review of the literature. Int J Surg Pathol. https://doi.org/10.1177/10668969241253197

Article  PubMed  Google Scholar 

Yeh YA, Yang S, Constantinescu M et al (2019) Prostatic adenocarcinoma with novel NTRK3 gene fusion: a case report. Am J Clin Exp Urol 7:341–345

PubMed  PubMed Central  Google Scholar 

Ling Q, Li B, Wu X et al (2018) The landscape of NTRK fusions in Chinese patients with solid tumor. Ann Oncol 29:822–823. https://doi.org/10.1093/annonc/mdy269.073

Article  Google Scholar 

Tomiyama E, Fujita K, Matsuzaki K et al (2022) EphA2 on urinary extracellular vesicles as a novel biomarker for bladder cancer diagnosis and its effect on the invasiveness of bladder cancer. Br J Cancer 127:1312–1323. https://doi.org/10.1038/s41416-022-01860-0

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hao Y, Li G (2020) Role of EFNA1 in tumorigenesis and prospects for cancer therapy. Biomed Pharmacother 130:110567. https://doi.org/10.1016/j.biopha.2020.110567

Article  CAS  PubMed  Google Scholar 

Wu S, Liu Y, Shi X, Zhou W, Zeng X (2023) Elaboration of NTRK-rearranged colorectal cancer: integration of immunoreactivity pattern, cytogenetic identity, and rearrangement variant. Dig Liver Dis 55:1757–1764. https://doi.org/10.1016/j.dld.2023.04.019

Article  CAS  PubMed  Google Scholar 

Endo Y, Watanabe T, Saito M et al (2022) A rare case of recurrent ovarian cancer with TPM3-NTRK1 gene rearrangement: a case report. Mol Clin Oncol 16:90. https://doi.org/10.3892/mco.2022.2523

Article  PubMed  PubMed Central  Google Scholar 

Drilon A (2019) TRK inhibitors in TRK fusion-positive cancers. Ann Oncol 30:823–830. https://doi.org/10.1093/annonc/mdz282

Article  Google Scholar 

Russo M, Misale S, Wei G et al (2016) Acquired resistance to the TRK inhibitor Entrectiinib in colorectal cancer. Cancer Discov 6:36–44. https://doi.org/10.1158/2159-8290.CD-15-0940

Article  CAS  PubMed  Google Scholar 

Cocco E, Schram MA, Kulick A et al (2019) Resistance to TRK inihibition mediated by convergent MAPK pathway activation. Nat Med 25:1422–1427. https://doi.org/10.1038/s41591-019-0542-z

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hatano K, Yamaguchi S, Nimura K et al (2013) Residual prostate cancer cells after docetaxel therapy increase the tumorigenic potential via constitutive signaling of CXCR4, ERK1/2 and c-Myc. Mol Cancer Res 11:1088–1100. https://doi.org/10.1158/1541-7786.MCR-13-0029-T

Article  CAS  PubMed  Google Scholar 

Fuse JM, Okada K, Oh-Hara T et al (2017) Mechanisms of resistance to NTRK inhibitors and therapeutic strategies in NTRK1-rearranged cancers. Mol Cancer Ther 16:2130–2143. https://doi.org/10.1158/1535-7163.MCT-16-0909

Article  CAS  PubMed  Google Scholar 

Matsushita M, Fujita K, Hatano K et al (2022) Connecting the dots between the gut-IGF-1-prostate axis: a role of IGF-1 in prostate carcinogenesis. Front Endocrinol (Lausanne) 13:852382. https://doi.org/10.3389/fendo.2022.852382

Article  PubMed  Google Scholar 

Doz F, van Tilburg CMV, Geoerger B et al (2022) Efficacy and safety of Larotrectinib in TRK fusion-positive primary central nervous system tumors. Neuro Oncol 24:997–1007. https://doi.org/10.1093/neuonc/noab274

Article  CAS  PubMed  Google Scholar 

Fischer H, Ullah M, de la Cruz CC et al (2020) Entrectinib, a TRK/ROS1 inhibitor with anti-CNS tumor activity: differentiation from other inhibitors in its class due to weak interaction with P-glycoprotein. Neuro Oncol 22:819–829. https://doi.org/10.1093/neuonc/noaa052

Article  CAS  PubMed  PubMed Central  Google Scholar 

Herberts C, Annala M, Sipola J et al (2022) Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer. Nature 608:199–208. https://doi.org/10.1038/s41586-022-04975-9

Article  CAS  PubMed  Google Scholar 

Armenia J, Wankowicz SAM, Liu D et al (2018) The long tail of oncogenic drivers in prostate cancer. Nat Genet 50:645–651. https://doi.org/10.1038/s41588-018-0078-z

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brastianos KP, Carter LS, Santagata S et al (2015) Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets. Cancer Discov 5:1164–1177. https://doi.org/10.1158/2159-8290.CD-15-0369

Article  CAS  PubMed  PubMed Central  Google Scholar